Bioimaging
Bioimaging brings together imaging scientists, clinicians, physicists, biologists and chemists to better understand the pathophysiology of disease through imaging. This rapidly growing field enables us to visualize physiological structures, measure biological functions, and evaluate cellular and molecular events without invasive procedures.
Using exciting new technologies such as high field magnetic resonance imaging, positron emission tomography, single photon emission computed tomography, optical imaging and computed tomography, we strive to develop anatomical and functional imaging biomarkers that provide additional insight into a drug’s effectiveness.
“We are fortunate to have a state-of-the-art imaging center with multiple imaging technologies. This gives us the capabilities and flexibility to develop and assess imaging biomarkers that help advance drug discovery at Bristol-Myers Squibb and ultimately, bring innovative new medicines to patients,” says Wendy Hayes, Ph.D., director of imaging, Oncology/Immunology.
We seek high performers with backgrounds in medical physics and biology or biomedical engineering, who are motivated by conducting leading-edge imaging science and learning new technologies.